Drugs / Typhoid Vaccine

Trials 2 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02415387 Jan 2014 → Apr 2021 depressive disorder, female breast carcinoma Ohio State University Comprehensive Cancer Center Completed No outcome recorded
Phase 11 trial
Phase 1 NCT01099631 Apr 2010 → Jan 2014 biliary tract cancer, hepatocellular carcinoma Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01582321 Background Mar 2012 → Dec 2016 Queen Mary University of London Completed No outcome recorded
Phase 11 trial
Phase 1 NCT02715635 Comparator Apr 2016 → Dec 2020 cardiovascular disorder Queen Mary University of London Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03889158 Background Mar 2019 → Mar 2020 University of Illinois at Chicago Terminated No outcome recorded
Phase not applicable1 trial
NCT02628054 Comparator Feb → Jul 2015 University of Oxford Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as typhoid vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02415387
4

NCT01582321

NCT03889158

NCT02715635

NCT02628054

Known as Salmonella typhimurium ClinicalTrials.gov intervention name — accepted as the source's own label NCT01099631
Modality Other / unclassified “attenuated strain of Salmonella typhimurium expressing human interleukin-2 (IL-2)” NCT01099631
Route Oral “will be given orally” NCT01099631